Clinical Trials in Multiple Myeloma


target mechanism of investigative drug


title of clinical trial






This trial is for people whose myeloma has come back or treatment has stopped working. Drugs can include cyclophosphamide, dexamethasone and ixazomib



Myeloma 12 (ACCORD)


This trial is for people who have had a stem cell transplant and who had no sign of their myeloma (in remission) for at least 12 months before it came back. The people taking part must be fit and healthy enough to have another stem cell transplant.





This study is for people whose myeloma has come back or continued to get worse after having at least 2 or 3 different types of standard treatment.





This trial is looking at treating newly diagnosed solitary bone plasmacytoma with lenalidomide and dexamethasone after having radiotherapy.





This is a study looking to treat people with myeloma who have had between 2-4 lines of treatment in the past, including lenalidomide. It will look at the effects of melflufan and dexamethasone vs pomalidomide and dexamethasone.





A trial for people with high risk multiple myeloma, looking at a novel combination of several anti-cancer drugs





A study looking at the effects of selinexor, bortezomib, and dexamethasone in patients with multiple myeloma which has come back after 1 to 3 lines of prior therapy.



This trial is for patients with smouldering myeloma, comparing subcutaneous daratumumab against active monitoring.